Schmid P, et al. - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer. ESMO Congress 2019, abstract LBA8_PR.
Promotie: Patiëntervaringen en risico's bij goedaardige levertumoren en -cysten
nov 2023 | Chirurgie, Hepatologie, Maag-darm-leveroncologie